Related Experiment Video
Updated: Jan 16, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors
Abstract:
Antigen (Ag) escape is a frequent mechanism of relapse after CAR-T therapy, even though only ∼1% of leukemic and ∼0.1% of lymphoma cells are Ag⁻ at baseline. In this study, we modeled extreme Ag heterogeneity (>20%) to define how Fas/FasL-dependent bystander killing contributes to tumor clearance. Across patient cohorts, Fas expression predicted survival after CD19 CAR-T therapy, particularly in CD19-low disease. In both murine and human systems, Fas-dependent bystander killing required Ag stimulation and cell contact, operated within a defined therapeutic window, and could eradicate large fractions of Ag⁻ tumors in vivo . Pharmacologic potentiation with inhibitor of apoptosis protein antagonists or genetic stabilization of CAR-T membrane-bound FasL enhanced bystander killing but simultaneously induced CD4⁺ T cell fratricide, which was rescued by CAR-T Fas knockout. Importantly, Fas sensitization also enabled bispecific antibody-redirected T cells to mediate bystander killing in resistant tumors. Finally, targeting tumor-associated macrophages triggered Fas-dependent clearance of neighboring tumor cells. These findings establish Fas-mediated bystander killing as a generalizable and therapeutically actionable axis to prevent Ag escape and broaden the scope of targeted T cell therapies.
Insights
Fas/FasL-dependent bystander killing can eradicate antigen-negative tumors after CAR-T therapy. Enhancing this killing mechanism, particularly in antigen-low disease, offers a new strategy to prevent cancer relapse.
Area of Science:
- Immunology
- Cancer Biology
- Cell Therapy
Background:
- Antigen escape is a major cause of relapse after CAR-T therapy, despite low baseline antigen-negative tumor cell percentages.
- Fas/FasL-mediated bystander killing is a potential mechanism to eliminate antigen-negative tumor cells.
Purpose of the Study:
- To investigate the contribution of Fas/FasL-dependent bystander killing to tumor clearance in models of extreme antigen heterogeneity.
- To define the conditions and therapeutic potential of enhancing Fas-mediated bystander killing to overcome antigen escape in CAR-T therapy.
Main Methods:
- Modeling extreme antigen heterogeneity in murine and human systems.
- Assessing Fas expression as a survival predictor after CD19 CAR-T therapy.
- Evaluating pharmacologic and genetic strategies to enhance Fas-dependent bystander killing.
- Investigating the role of tumor-associated macrophages in Fas-mediated tumor cell clearance.
Main Results:
- Fas expression correlated with improved survival after CD19 CAR-T therapy, especially in CD19-low disease.
- Fas-dependent bystander killing, requiring antigen stimulation and cell contact, eradicated antigen-negative tumors in vivo within a specific therapeutic window.
- Enhancing bystander killing via apoptosis protein antagonists or stabilized FasL led to CD4+ T cell fratricide, rescued by CAR-T Fas knockout.
- Fas sensitization enabled bystander killing by bispecific antibody-redirected T cells in resistant tumors.
- Targeting tumor-associated macrophages induced Fas-dependent clearance of neighboring tumor cells.
Conclusions:
- Fas-mediated bystander killing is a therapeutically actionable mechanism to prevent antigen escape after CAR-T therapy.
- This pathway can be pharmacologically or genetically enhanced to broaden the efficacy of T cell-based cancer therapies.
- Targeting tumor-associated macrophages can also leverage Fas-dependent pathways for tumor cell elimination.
